Drug intelligence / Profile preview

anti-PSCA-VC-PAB-MMAE

Development stage: Preclinical
Lead developer: University of California, Los Angeles
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

anti-PSCA-VC-PAB-MMAE is a novel antibody-drug conjugate (ADC) designed for the treatment of prostate cancer. It targets the prostate stem cell antigen (PSCA), a cell-surface protein highly overexpressed in prostate cancer and advanced disease states. The ADC consists of a human anti-PSCA monoclonal antibody (clone A2) conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a cathepsin-cleavable valine-citrulline-p-aminobenzyloxycarbonyl (VC-PAB) linker. Upon binding to PSCA and subsequent internalization, the linker is cleaved, releasing MMAE to inhibit tubulin polymerization, leading to cell cycle arrest and apoptosis. Preclinical data presented at AACR 2026 demonstrated high binding affinity, potent cytotoxicity against PSCA-positive cell lines, and robust plasma stability.

Other names: A2-VC-PAB-MMAEA-2-VC-PAB-MMAEA 2-VC-PAB-MMAE

Targets

TUBB (Tubulin (alpha and beta subunits))PSCA (Prostate stem cell antigen)

Beyond the preview

Go deeper on anti-PSCA-VC-PAB-MMAE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-PSCA-VC-PAB-MMAE.

Explore the full profile